Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 17.05 |
| Open | 17.08 |
| Bid | 17.13 x 3200 |
| Ask | 17.25 x 3200 |
| Day's range | 17.06 - 17.25 |
| 52-week range | 15.30 - 20.00 |
| Volume | 1,928,250 |
| Avg. volume | 4,113,183 |
| Market cap | 54.066B |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | 32.86 |
| EPS (TTM) | 0.52 |
| Earnings date | N/A |
| Forward dividend & yield | 0.85 (4.93%) |
| Ex-dividend date | 29 Sep 2020 |
| 1y target est | 23.01 |
- Motley Fool
Why Molecular Templates Stock Crashed Today
Shares of Molecular Templates (NASDAQ: MTEM) closed down 23.6% on Monday. The big drop came after the company announced that it was resuming full rights of engineered toxin bodies (ETB) candidate TAK-169 from Takeda (NYSE: TAK). Molecular Templates also said that it's discontinuing the development of MT-3724, another experimental ETB.
- Business Wire
Takeda Hosts Wave 1 Pipeline Market Call
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years.
- Business Wire
Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group ("Orifarm") for a total value of up to $670 million USD. The portfolio includes approximately 130 over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland. This divestment agreement was first announced in April 2020.
